Oaktree Acquisition Corp. III Life Sciences
Business
Oaktree Acquisition Corp. III Life Sciences is a blank-check company formed to identify and execute a merger or acquisition with one or more operating businesses, with a focus on healthcare and healthcare-related industries including biopharmaceuticals, medical devices, diagnostics, and specialized healthcare services. The company leverages Oaktree Capital's investment platform, global relationships, and specialized life sciences lending team to source and evaluate potential business combination targets. The company intends to target fundamentally healthy North American, British, or European companies in the healthcare sector where its management team has demonstrated investment and operational expertise.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| General and administrative expenses | 1 | |
| Loss from operations | −1 | |
| Change in fair value of over-allotment liability | 0 | |
| Interest earned on cash held in Trust Account | 8 | |
| Total other income | 8 | |
| Net income | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 |
|---|---|---|---|---|
| Cash | 1 | 1 | — | |
| Prepaid expenses | 113,275 | 201,281 | — | |
| Total current assets | 2 | 2 | — | |
| Long-term prepaid insurance | 0 | 113,275 | — | |
| Cash held in Trust Account | 202 | 194 | — | |
| TOTAL ASSETS | 203 | 195 | — | |
| Accounts payable and accrued expenses | 501,968 | 535,515 | — | |
| Accrued offering costs | 0 | 179,984 | — | |
| Due to related party | 785,857 | 0 | — | |
| Promissory note - related party | 11,824 | 11,824 | — | |
| Total current liabilities | 1 | 727,323 | — | |
| Deferred legal fees | 299,088 | 299,088 | — | |
| Deferred underwriting fee payable | 7 | 7 | — | |
| Total Liabilities | 8 | 8 | — | |
| Commitments and Contingencies (Note 5) | — | — | — | |
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 19,199,029 issued and outstanding as of December 31, 2025 and 2024; at redemption value of $10.50 and $10.08 per share as of December 31, 2025 and 2024, respectively | 202 | 194 | — | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | — | |
| Additional paid-in capital | 0 | 0 | — | |
| Accumulated deficit | −7 | −6 | — | |
| Total Shareholders' Deficit | −7 | −6 | 0 | |
| TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT | 203 | 195 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| Payment of operating costs through promissory note | 0 | |
| Prepaid expenses | 88,005 | |
| Long Term prepaid insurance | 113,275 | |
| Accounts payable and accrued expenses | −33,545 | |
| Accrued offering costs | −179,984 | |
| Due to related party | 785,857 | |
| Net cash used in operating activities | −422,079 | |
| Investment of cash in Trust Account | 0 | |
| Cash withdrawn from Trust Account for allowable working capital purposes | 500,000 | |
| Net cash provided by investing activities | 500,000 | |
| Proceeds from sale of Units, net of underwriting discounts paid | 0 | |
| Proceeds from sale of Private Placement Units | 0 | |
| Repayment of promissory noterelated party | 0 | |
| Net cash provided by financing activities | 0 | |
| Net Change in Cash | 77,921 | |
| Offering costs included in accrued offering costs | 0 | |
| Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares | 0 | |
| Deferred offering costs paid through promissory noterelated party | 0 | |
| Prepaid services contributed by Sponsor through promissory noterelated party | 0 | |
| Deferred underwriting fee payable | 0 | |
| Deferred legal fee payable | 0 | |
| Forfeiture of Founder Shares | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Oaktree Acquisition Corp. III Life Sciences's CIK number?
Oaktree Acquisition Corp. III Life Sciences's SEC CIK number is 0002029769 (2029769). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Oaktree Acquisition Corp. III Life Sciences's SEC filings?
All of Oaktree Acquisition Corp. III Life Sciences's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.